小剂量丙酸氟替卡松与沙美特罗联合用于慢性阻塞性肺病患者。

IF 1 Q4 RESPIRATORY SYSTEM
Hideki Yasui, Naoki Inui, Tomoyuki Fujisawa, Masato Karayama, Noriyuki Enomoto, Yutaro Nakamura, Shigeki Kuroishi, Hisano Ohba, Koshi Yokomura, Jun Sato, Masaki Sato, Naoki Koshimizu, Mikio Toyoshima, Takashi Yamada, Masafumi Masuda, Toshihiro Shirai, Takafumi Suda
{"title":"小剂量丙酸氟替卡松与沙美特罗联合用于慢性阻塞性肺病患者。","authors":"Hideki Yasui, Naoki Inui, Tomoyuki Fujisawa, Masato Karayama, Noriyuki Enomoto, Yutaro Nakamura, Shigeki Kuroishi, Hisano Ohba, Koshi Yokomura, Jun Sato, Masaki Sato, Naoki Koshimizu, Mikio Toyoshima, Takashi Yamada, Masafumi Masuda, Toshihiro Shirai, Takafumi Suda","doi":"10.1177/1179548418771702","DOIUrl":null,"url":null,"abstract":"<p><p>Inhaled corticosteroids are widely used in the treatment of chronic obstructive pulmonary disease (COPD). However, their use has been questioned for appropriate dose and a possible increased risk of pneumonia. Here, we reviewed patients with COPD who had received fluticasone-salmeterol combination treatment using data from a linked electronic medical record database. A total of 180 patients received salmeterol with 250 µg fluticasone propionate twice daily and 78 received salmeterol and 100 µg fluticasone propionate twice daily. In both groups, there was no difference in the improved forced expiratory volume in 1 second and COPD assessment test score and the proportion of patients with exacerbations. Although the incidence of common toxicity was approximately equal, that of pneumonia was much higher in the 250 µg group (8.9% vs 1.3%, <i>P</i>=.01). The beneficial effects of inhaled corticosteroids might be obtained at lower doses.</p>","PeriodicalId":44269,"journal":{"name":"Clinical Medicine Insights-Circulatory Respiratory and Pulmonary Medicine","volume":"12 ","pages":"1179548418771702"},"PeriodicalIF":1.0000,"publicationDate":"2018-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a8/0d/10.1177_1179548418771702.PMC5987896.pdf","citationCount":"0","resultStr":"{\"title\":\"Low-dose Fluticasone Propionate in Combination With Salmeterol in Patients With Chronic Obstructive Pulmonary Disease.\",\"authors\":\"Hideki Yasui, Naoki Inui, Tomoyuki Fujisawa, Masato Karayama, Noriyuki Enomoto, Yutaro Nakamura, Shigeki Kuroishi, Hisano Ohba, Koshi Yokomura, Jun Sato, Masaki Sato, Naoki Koshimizu, Mikio Toyoshima, Takashi Yamada, Masafumi Masuda, Toshihiro Shirai, Takafumi Suda\",\"doi\":\"10.1177/1179548418771702\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Inhaled corticosteroids are widely used in the treatment of chronic obstructive pulmonary disease (COPD). However, their use has been questioned for appropriate dose and a possible increased risk of pneumonia. Here, we reviewed patients with COPD who had received fluticasone-salmeterol combination treatment using data from a linked electronic medical record database. A total of 180 patients received salmeterol with 250 µg fluticasone propionate twice daily and 78 received salmeterol and 100 µg fluticasone propionate twice daily. In both groups, there was no difference in the improved forced expiratory volume in 1 second and COPD assessment test score and the proportion of patients with exacerbations. Although the incidence of common toxicity was approximately equal, that of pneumonia was much higher in the 250 µg group (8.9% vs 1.3%, <i>P</i>=.01). The beneficial effects of inhaled corticosteroids might be obtained at lower doses.</p>\",\"PeriodicalId\":44269,\"journal\":{\"name\":\"Clinical Medicine Insights-Circulatory Respiratory and Pulmonary Medicine\",\"volume\":\"12 \",\"pages\":\"1179548418771702\"},\"PeriodicalIF\":1.0000,\"publicationDate\":\"2018-05-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a8/0d/10.1177_1179548418771702.PMC5987896.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Medicine Insights-Circulatory Respiratory and Pulmonary Medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1177/1179548418771702\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2018/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q4\",\"JCRName\":\"RESPIRATORY SYSTEM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Medicine Insights-Circulatory Respiratory and Pulmonary Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/1179548418771702","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2018/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}
引用次数: 0

摘要

吸入皮质类固醇被广泛用于治疗慢性阻塞性肺病(COPD)。然而,人们对其使用剂量是否适当以及是否会增加肺炎风险提出了质疑。在此,我们利用链接电子病历数据库中的数据,对接受过氟替卡松-沙美特罗联合治疗的慢性阻塞性肺病患者进行了回顾。共有 180 名患者接受了沙美特罗和 250 µg 丙酸氟替卡松联合治疗,每日两次;78 名患者接受了沙美特罗和 100 µg 丙酸氟替卡松联合治疗,每日两次。两组患者的一秒钟用力呼气量和慢性阻塞性肺病评估测试得分以及病情加重的患者比例均无差异。虽然常见毒性的发生率大致相同,但 250 µg 组的肺炎发生率要高得多(8.9% 对 1.3%,P=.01)。吸入皮质类固醇的有益作用可能会在较低剂量下获得。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Low-dose Fluticasone Propionate in Combination With Salmeterol in Patients With Chronic Obstructive Pulmonary Disease.

Low-dose Fluticasone Propionate in Combination With Salmeterol in Patients With Chronic Obstructive Pulmonary Disease.

Low-dose Fluticasone Propionate in Combination With Salmeterol in Patients With Chronic Obstructive Pulmonary Disease.

Low-dose Fluticasone Propionate in Combination With Salmeterol in Patients With Chronic Obstructive Pulmonary Disease.

Inhaled corticosteroids are widely used in the treatment of chronic obstructive pulmonary disease (COPD). However, their use has been questioned for appropriate dose and a possible increased risk of pneumonia. Here, we reviewed patients with COPD who had received fluticasone-salmeterol combination treatment using data from a linked electronic medical record database. A total of 180 patients received salmeterol with 250 µg fluticasone propionate twice daily and 78 received salmeterol and 100 µg fluticasone propionate twice daily. In both groups, there was no difference in the improved forced expiratory volume in 1 second and COPD assessment test score and the proportion of patients with exacerbations. Although the incidence of common toxicity was approximately equal, that of pneumonia was much higher in the 250 µg group (8.9% vs 1.3%, P=.01). The beneficial effects of inhaled corticosteroids might be obtained at lower doses.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
4.20
自引率
0.00%
发文量
9
审稿时长
8 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信